Penumbra (NYSE:PEN) Posts Earnings Results, Beats Expectations By $0.09 EPS

Penumbra (NYSE:PEN) released its quarterly earnings results on Tuesday. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09, Zacks reports. Penumbra had a net margin of 2.97% and a return on equity of 8.99%. Penumbra updated its FY 2025 guidance to EPS.

Penumbra Stock Up 0.9 %

Shares of PEN traded up $2.32 during mid-day trading on Tuesday, hitting $270.99. 711,992 shares of the company’s stock were exchanged, compared to its average volume of 480,734. The firm has a fifty day moving average of $255.58 and a two-hundred day moving average of $225.29. Penumbra has a twelve month low of $148.00 and a twelve month high of $277.89. The stock has a market cap of $10.40 billion, a price-to-earnings ratio of 315.10, a P/E/G ratio of 1.92 and a beta of 0.53. The company has a quick ratio of 3.25, a current ratio of 5.82 and a debt-to-equity ratio of 0.02.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Truist Financial boosted their price target on shares of Penumbra from $240.00 to $285.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Robert W. Baird boosted their price target on shares of Penumbra from $244.00 to $248.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a research report on Thursday, October 31st. Piper Sandler increased their target price on shares of Penumbra from $235.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 20th. Finally, Wells Fargo & Company upgraded shares of Penumbra from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $190.00 to $275.00 in a research report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $261.36.

Insider Transactions at Penumbra

In related news, EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $244.49, for a total value of $146,694.00. Following the transaction, the executive vice president now directly owns 63,444 shares in the company, valued at approximately $15,511,423.56. This trade represents a 0.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Adam Elsesser sold 15,000 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $237.28, for a total transaction of $3,559,200.00. Following the completion of the transaction, the chief executive officer now owns 852,582 shares in the company, valued at $202,300,656.96. The trade was a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,219 shares of company stock worth $7,985,639 in the last 90 days. 5.00% of the stock is owned by insiders.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.